Novartis to merge with MorphoSys AG after successful acquisition and delisting agreement
Acquiring Company
Novartis
Acquired Company
Novartis BidCo AG
Switzerland
BavariaBiotechnologyHealth CarepharmaceuticalsBiotechnologyHealth CareTherapeuticsBiopharmaDescription
Novartis, a global medicines company, has successfully acquired majority ownership of MorphoSys AG and initiated a delisting agreement to squeeze-out the minority shareholders. The intention to merge MorphoSys into Novartis reflects a strategic move to further strengthen Novartis' position in the biopharmaceutical industry.
Quick answer
Novartis is acquiring Novartis BidCo AG, announced June 20, 2024. Novartis is based in Switzerland.
- How much did Novartis pay for Novartis BidCo AG?
- The deal value was not disclosed.
- What does Novartis do?
- Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel.
- Where are Novartis and Novartis BidCo AG based?
- Novartis is based in Switzerland. Novartis BidCo AG is based in Bavaria, Germany.
- Who are the decision-makers at Novartis?
- Fundz holds 1 contact at Novartis. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in pharmaceuticals and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie finalizes acquisition of Landos Biopharma, Inc. to advance treatment for ulcerative colitis and Crohn's disease (May 23, 2024)
- Novartis BidCo Germany AG to Merge Squeeze-out MorphoSys AG’s Minority Shareholders (June 20, 2024)
- Lantheus Holdings, Inc. acquires Meilleur Technologies, Inc. to expand Alzheimer’s diagnostic capabilities (July 15, 2024)
- Ligand Pharmaceuticals to acquire APEIRON Biologics AG to enhance royalty portfolio (July 8, 2024)
- Cycle Pharmaceuticals proposes to acquire Vanda Pharmaceuticals for $8.00 per share (June 6, 2024)
- Incyte completes acquisition of Escient Pharmaceuticals to strengthen its Inflammation and Autoimmunity portfolio (May 30, 2024)
Who to call at Novartis, and when
When Novartis changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Novartis raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Novartis, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Novartis. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Novartis makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Novartis BidCo AG?
Novartis BidCo AG was acquired by Novartis, based in Switzerland. The deal was reported on June 20, 2024. Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel. Novartis is publicly traded (NVS) and operates in Biotechnology.
When did Novartis acquire Novartis BidCo AG?
Novartis's acquisition of Novartis BidCo AG was reported on June 20, 2024. Novartis, a global medicines company, has successfully acquired majority ownership of MorphoSys AG and initiated a delisting agreement to squeeze-out the minority shareholders. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Novartis BidCo AG do?
Novartis BidCo AG is the company acquired in this transaction. It is privately held, operating in Biotechnology, and is based in Bavaria.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.